- Home
- SNTI
as 02-21-2025 4:00pm EST
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 21.3M | IPO Year: | N/A |
| Target Price: | $12.00 | AVG Volume (30 days): | 30.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -15.59 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.52 - $16.94 | Next Earning Date: | 03-20-2025 |
| Revenue: | N/A | Revenue Growth: | -40.25% |
| Revenue Growth (this year): | 11.52% | Revenue Growth (next year): | 78.57% |
Stock Insider Trading Activity of Senti Biosciences Inc. (SNTI)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Rajangam Kanya | SNTI | Pres. & Chief Med. & Dev. Off. | Feb 4 '25 | Sell | $4.22 | 1,479 | $6,074.13 | 8,803 | |
| Lu Timothy K | SNTI | CEO | Feb 4 '25 | Sell | $4.22 | 4,467 | $18,338.74 | 82,627 |
Latest Senti Biosciences Inc. News
SNTI Breaking Stock News: Dive into SNTI Ticker-Specific Updates for Smart Investing
Simply Wall St.
a month ago
US Penny Stocks To Watch In January 2025
GlobeNewswire
2 months ago
Senti Bio Announces Additional $11.5 Million of Financing
MT Newswires
2 months ago
Senti Biosciences Reports First Patient Dosed in Trial of SN301A in Hepatocellular Carcinoma
GlobeNewswire
2 months ago
Senti Bio Announces First Patient Dosed in Clinical Trial of SN301A in Hepatocellular Carcinoma in Collaboration with Celest Therapeutics
TipRanks
3 months ago
Senti Bio price target raised to $12 from $10 at Chardan
GlobeNewswire
3 months ago
Senti Biosciences Announces New Employment Inducement Grants
Zacks
3 months ago
SNTI Stock Skyrockets on Initial Data From Phase I Cancer Study
TipRanks
3 months ago
Senti Bio reports positive initial clinical data from Phase 1 trial of SENTI-202
Compare SNTI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SNTI Senti Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.